Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 13, 2021
Event: Entry into a Material Definitive Agreement for an underwriting of common stock.
Key Financial Metrics
This filing reports on a specific capital raising event rather than periodic operating results. Key financial figures related to the transaction include:
- Shares Issued: 1,000,000 shares of Common Stock.
- Public Offering Price: $54.50 per share.
- Net Proceeds: Approximately $51.0 million (after underwriting discounts, commissions, and estimated offering expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 150,000 additional shares.
Note: The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels as this is a transaction report, not a financial statement.
Material Changes
The primary material change is the increase in the company's equity capital and cash liquidity resulting from the closing of the offering on July 16, 2021. The company received net proceeds of approximately $51.0 million, significantly altering its cash position compared to the pre-offering period.
Guidance, Outlook, and Risks
Management Commentary and Lock-Up: The Company and all directors and executive officers agreed to a 90-day lock-up period, prohibiting the sale or transfer of Common Stock held by them without the written consent of the underwriters, subject to certain exceptions.
Contingencies and Risks: The Company agreed to indemnify the underwriters against certain liabilities, including those under the Securities Act of 1933, or to contribute to payments required by the underwriters due to such liabilities.
Outlook: The filing does not contain specific forward-looking guidance regarding future revenue or earnings.
Investor Verification Checklist
- Verify the final closing date of the offering (July 16, 2021) and confirm the exact net proceeds received.
- Confirm whether the underwriters exercised the option to purchase the additional 150,000 shares within the 30-day window.
- Review the attached Underwriting Agreement (Exhibit 1.1) for specific details on indemnification obligations and lock-up exceptions.
- Check subsequent filings to determine how the $51.0 million in net proceeds was utilized (e.g., debt repayment, R&D, working capital).